Join IAG’s Bio Partnering Team at Bio CEO and Investor Conference 2022
Our Bio-Partnering will attend Bio CEO and Investor Conference, 14-17 February 2022.
IAG’s partnering team are focused on building a diversified portfolio of innovative life science companies at various stages of clinical development.
IAG’s current portfolio consists of 10 biotech, pharma and digital health companies.
By bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry.
Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: https://www.ia-grp.com/trial-solutions/bio-partnering/
About Bio CEO and Investor:
The BIO CEO and Investor is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings. Since its inception 18 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin